A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough

Trial Profile

A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Cough
  • Focus Therapeutic Use
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 22 May 2017 According to a Merck AG media release, primary endpoint of reduction in Cough Frequency for lower doses (7.5 mg and 20 mg Gefapixant Vs. placebo) safety_issue: No, description: Objective cough monitoring - 24 hour, sound recording time_frame: 12 weeks has not been met.
    • 22 May 2017 According to a Merck AG media release, the results of this study were presented at the American Thoracic Society 113th Annual Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top